Cetirizine Hydrochloride

Press Release Nicox: 2024 Ordinary Shareholder Meeting to be held on June 28th, 2024May 24, 2024 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, convenes an ordinary shareholder meeting on Friday June 28th, 2024 at 2:30 pm CEST in the offices of BuroClub – Drakkar 2 – Bâtiment D – 2405 route des Dolines – 06560 Valbonne Sophia Antipolis – France.The documents mentioned in article R.22.10-23 of the French Code de commerce, including a proxy voting form, will be sent to the shareholders upon written request. These documents will also be made available to shareholders at the headquarters of the Company and on its website (www.nicox.com) by June 13th, 2024.Shareholders may vote by proxy, by internet or by attending the shareholder meeting in person. A guide explaining how to vote, and notably how to vote by internet, is available on the Company’s website. Shareholders may also contact the Company’s Investor Relations team at ag2024nicox@nicox.com for any question on the voting process.In the event the quorum is not reached on first call, Nicox will convene an ordinary shareholder meeting on a second call on Monday July 15th, 2024 at 2:30 pm CEST in the offices of BuroClub – Drakkar 2 – Bâtiment D – 2405 route des Dolines – 06560 Valbonne Sophia Antipolis – France.About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.comAnalyst coverageBryan, Garnier & Co Eric Yoo Paris, FranceH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.Contacts NicoxGavin SpencerChief Executive Officer+33 (0)4 97 24 53 00communications@nicox.com Media / Investors Sophie Baumont Cohesion Bureau +33 6 27 74 74 49 sophie.baumont@cohesionbureau.comNicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_OGM June 2024_Annoucement

From the outset, GSK has said it planned to sell down most of its stake in Haleon. Right on the heels of a similar move by Johnson & Johnson, GSK has agreed to sell the rest of its stake in the consumer healthcare business it spun out back in 2022. Thursday, GSK revealed its intent to sell (PDF) its remaining 4.2% holding in Haleon, representing around 385 million shares. A day later, GSK said (PDF) the agreement raised proceeds of 1.248 billion pounds sterling ($1.58 billion). The shares are being offered to institutional investors by Goldman Sachs and Bank of America Securities, the company said.  GSK completed the spinoff of its consumer health division—formerly a joint venture between the British pharma and Pfizer—in July 2022. At the time, GSK held a roughly 13% stake in Haleon, which is responsible for household brands like Advil, Sensodyne, Tums and Theraflu. From the outset, GSK said it planned to sell down most of its stake in Haleon. The company sold share tranches twice last year and again in January. All told, GSK has pawned off around 1.2 billion Haleon shares for about 3.9 billion pounds (nearly $5 billion), the company said in its Friday filing. For its part, Pfizer—which came out of the 2022 demerger holding 32% of Haleon’s shares—said in March that it would whittle down its stake to 24% by selling 630 million shares in a public offering. Large pharmas separating their consumer health ventures has become a notable industry trend in recent years, with companies such as J&J and Merck charting similar moves. In J&J’s case, the drugmaker Monday said it planned to exit ownership of its spinoff—Kenvue—completely through a 182.33 million share “debt-for-equity” exchange. As the successor to J&J’s consumer health business, Kenvue markets popular products like Tylenol, Neutrogena, Listerine and Zyrtec. Editor's note: This story has been updated with additional details from GSK.